|
|
|
Medical Countermeasures Against Radiological and Nuclear Threats |
|
|
Fiscal Year (FY) 2005-2007 AwardeesContracts | Grants | Other Funding Contract AwardeesMedical Countermeasures Against Radiological Threats: Product Development Support Services (FY 2005)Development of Improved DTPA for Radionuclide Chelation (FY 2006)Grant AwardeesCenters for Medical Countermeasures Against Radiation (CMCR) (FY 2005)CMCR Individual Project Descriptions (PDF) - Columbia University Medical Center, New York, NY
- David Brenner
Center for High Throughput, Minimally Invasive, Radiation Biodosimetry - Dana-Farber Cancer Institute, Boston, MA
Alan D’Andrea Dana-Farber/Harvard Center for Medical Countermeasures Against Radiation - Duke University Medical Center, Durham, NC
Nelson Chao Radiation Countermeasures Centers of Research Excellence (RadCCORE) - Fred Hutchinson Cancer Research Center, Seattle, WA
George Georges Radiation Dose-Dependent Interventions - Medical College of Wisconsin, Milwaukee, WI
John Moulder Post-Irradiation Intervention to Mitigate and Treat Non-Hematological Injuries - University of California David Geffen School of Medicine, Los Angeles, CA
William McBride UCLA Center for Biological Radioprotectors - University of Pittsburgh, Pittsburgh, PA
Joel Greenberger Mitochondrial Targeting Against Radiation Damage - University of Rochester Medical Center, Rochester, NY
Paul Okunieff Center for Biophysical Assessment and Risk Management Following Radiation
Protecting the Immune System Against Radiation (FY 2005)Radionuclide Decorporation Agents for Radiation/Nuclear Emergencies (FY 2006)- Pacific Northwest National Laboratory, Richland, WA
Tatiana G. Levitskaia Biomaterials as Decorporation Agents for Radionuclides - Pacific Northwest National Laboratory, Richland, WA
Charles Timchalk Development of Selective Nanoporous Sorbents for Radionuclide Decorporation - University of California/Lawrence Berkeley National Laboratory, Berkeley, CA
Kenneth N. Raymond Biomimetic Lanthanide & Actinide Decorporation Agents: Preclinical Development - University of Florida, Gainesville, FL
Raymond J. Bergeron Desferrithiocin Analogue Actinide Decorporation Agents - University of Utah School of Medicine, Salt Lake City, UT
Scott C. Miller Amphipathic Oral Chelators and Radionuclide Contamination
Medical Countermeasures to Restore Gastrointestinal Function after Radiation Exposure: Project Bioshield (RC1) (FY 2007)Medical Countermeasures to Enhance Platelet Regeneration and Increase Survival Following Radiation Exposure (RC1) (FY 2008) - Amelia M. Bartholomew, M.D., University of Illinois at Chicago, IL
- George Georges, M.D. Fred Hutchinson Cancer Research Center, Seattle, WA
- Andrei V. Gudkov, Ph.D., Cleveland Biolabs, Inc., Buffalo, NY
- Holger Karsunky, Ph.D., Cellerant Therapeutics, Inc., San Carlos, CA
- Kathleen E. Rodgers, Ph.D., University of Southern California, Los Angeles
Mechanisms, Diagnosis, and Treatment of Radiation Injury from a Nuclear Accident or Terrorist Attack (R01) (FY 2008 - R. Shane Addleman, D.Sc., Battelle Pacific Northwest Laboratories, Richland, WA
- Susan M. Bailey, Ph.D., Colorado State University, Fort Collins
- Tao Cheng, M.D., University of Pittsburgh at Pittsburgh, PA
- Andrei V. Gudkov, Ph.D., Roswell Park Cancer Institute Corporation, Buffalo, NY
- David G. Kirsch, M.D., Ph.D., Duke University, Durham, NC
- James Palis, M.D., University of Rochester, NY
- Amanda G. Paulovich, M.D., Ph.D., Fred Hutchinson Cancer Research Center, Seattle, WA
- Gabor J. Tigyi, M.D., Ph.D., University of Tennessee Health Science Center, Memphis
- Marcel R.M. van den Brink, M.D., Ph.D., Memorial Sloan-Kettering Institute for Cancer Research, New York, NY
- Daohong Zhou, M.D., Medical University of South Carolina, Charleston
Radiation Combined Injury: Radiation Exposure in Combination with Burn, Wound, Trauma, or Infection (Phased Innovation Award [R21/R33] (FY 2008 - Shyam Biswal, Ph.D., Johns Hopkins University, Baltimore, MD
- Nelson J. Chao, M.D., Duke University, Durham, NC
- John R. Fike, Ph.D., University of California San Francisco
- M. Waleed Gaber, Ph.D., and Duane D. Miller, Ph.D., University of Tennessee Health Science Center, Memphis
- Juliann G. Kiang, Ph.D., Armed Forced Radiobiology Research Institute, Bethesda, MD
- Elizabeth J. Kovacs, Ph.D., Loyola University Chicago, IL
- James A. Lederer, Ph.D., Brigham and Women’s Hospital, Boston, MA
- David M. Rocke, Ph.D., and R. Rivkah Isseroff, M.D., University of California Davis
- Ping Wang, M.D., Feinstein Institute for Medical Research, Manhasset, NY
- Hartmut Weiler, Ph.D., Blood Center of Wisconsin, Incorporated, Milwaukee
Other Funding Armed Forces Radiobiology Research Institute Program BackgroundEstablished in 2005, the Inter-Agency Agreement between the NIAID and the Armed Forces Radiobiology Research Institute (AFRRI) funds research in several areas related to the challenges encountered following radiological or nuclear events. These include: 1) identifying who has been exposed to radiation and estimating the dose that they have received, and 2) providing countermeasures to mitigate or treat radiation injury. To this end, AFRRI is funded to establish inter-laboratory cytogenetics comparisons, and automate the detection of radiation-induced changes in the DNA, with the hope that this will speed the triage of potentially radiation-exposed populations in the wake of a terrorist attack. Another aspect of the funding is the screening of potential countermeasures, to determine their efficacy in treating radiation damage in a rodent survival model. Research HighlightsFunding through the IAA with AFRRI has led to the first inter-laboratory comparison of the DNA dicentric assay since 1988. Long recognized as the gold standard for determination of radiation exposure, the dicentric assay has traditionally been a very time-consuming and low-throughput means of determining radiation dose received. In addition to validating use of the assay across 5 international laboratories, parallel NIAID-funded work at AFRRI has automated dicentric sample processing for triage of large populations, with a throughput of approximately 500 samples per laboratory per week. Taken together, these advancements represent important steps toward establishing a domestic network of biodosimetry laboratories, similar to those already in place in Canada and across Europe. In addition, to date AFRRI has screened more than 10 potential countermeasures, using their mouse model of radiation exposure. Program BackgroundThe National Institute of Allergy and Infectious Diseases (NIAID) and the National Cancer Institute (NCI) are cooperating on specific research and development projects that fall within the following general areas: 1) development of safe and effective medical countermeasures to prevent, mitigate, and treat the immediate and long-term medical effects of ionizing radiation; 2) improvement of the basic understanding of radiation-related health risks associated with types and levels of radiation exposure (epidemiology & dosimetry), mechanisms of radiation injury, and host responses; and, 3) development of biology-based diagnostic assays or biomarkers to assess cellular and tissue damage following exposure to ionizing radiation. The following laboratories/programs within intramural NCI are being funded: Research HighlightsScientific accomplishments for this program include: - Finding of a large bystander effect in 3-dimensional skin and airway radiation exposure models. This has implications for effects of partial body irradiations or inhomogeneous exposures.
- Demonstration of a clear separation in metabolomic signatures between sham and irradiated in vitro samples, with little variation between sham-irradiated cells, and identification of several candidate metabolomic markers for radiation exposure.
- Analysis of I-131 biokinetic data from 140 patients treated with I-131 for hyperthyroid, EPR analysis of 103 teeth from Semipalatinsk, Kazakhstan populations exposed to radiation, and testing of a novel biodosimetry system based on optically stimulated luminescence (OSL).
- Synthesis of 8 nitroxide analogs and irradiation of 1,275 mice (2 strains) in order to evaluate the efficacy of Tempol food in minimizing radiation-induced carcinogenesis.
back to top |
|
Highlights
RFA-DK-08-010: Intestinal Stem Cell Consortium (U01) - Co-Funded by the NIAID Radiation/Nuclear Program. Receipt date: March 18, 2009.
Pre-Solicitation Notice issued by BARDA, HHS, January 16, 2009: Advanced Therapeutics for Treating Neutropenia Resulting from Acute Exposure to Ionizing Radiation
Presolicitation Notice Issued by BARDA, HHS, January 16, 2009: Point of Care of High-Throughput Biological Assays for Determining Absorbed Ionizing Radiation Dose (Biodosimetry) after Radiologic and Nuclear Events.
See Also
Radiological and Nuclear Threats News Releases
Division of Allergy, Immunology, and Transplantation (DAIT)
Biodefense—The NIAID Biodefense Web site includes biodefense-related information for biomedical researchers, the public, and the media. |
|
|
|
|
|